EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

Beate Kampmann, Shabir A Madhi iD, Iona Munjal, Eric A F Simões, Barbara A Pahud, Conrado Llapur, Jeffrey Baker, Gonzalo Pérez Marc, David Radley, Emma Shittu, Julia Glanternik iD, Hasra Snaggs und 30 weitere

New England Journal of Medicine · 20.04.2023 · 388 (16) · 1451-1464

DOI: 10.1056/nejmoa2216480 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 20.04.2023. Verfasst von Beate Kampmann und 41 weiteren Autor:innen. Beteiligte Einrichtung: From the Medical Research Council Unit the Gambia, London School of Hygiene and Tropical Medicine, Fajara, Gambia (B.K.); the Institute for Internati…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Tract Infections. Die Arbeit wurde bisher 1005-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Medical Research Council, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain. METHODS: In this phase 3, double-blind trial conducted in 18 countries, we randomly assigned, in a 1:1 ratio, pregnant women at 24 through 36 weeks' gestation to receive a single intramuscular injection of 120 μg of a bivalent RSV prefusion F protein-based (RSVpreF) vaccine or placebo. The two primary efficacy end points were medically attended severe RSV-associated lower respiratory tract illness and medically attended RSV-associated lower respiratory tract illness in infants within 90, 120, 150, and 180 days after birth. A lower boundary of the confidence interval for vaccine efficacy (99.5% confidence interval [CI] at 90 days; 97.58% CI at later intervals) greater than 20% was considered to meet the success criterion for vaccine efficacy with respect to the primary end points. RESULTS: At this prespecified interim analysis, the success criterion for vaccine efficacy was met with respect to one primary end point. Overall, 3682 maternal participants received vaccine and 3676 received placebo; 3570 and 3558 infants, respectively, were evaluated. Medically attended severe lower respiratory tract illness occurred within 90 days after birth in 6 infants of women in the vaccine group and 33 infants of women in the placebo group (vaccine efficacy, 81.8%; 99.5% CI, 40.6 to 96.3); 19 cases and 62 cases, respectively, occurred within 180 days after birth (vaccine efficacy, 69.4%; 97.58% CI, 44.3 to 84.1). Medically attended RSV-associated lower respiratory tract illness occurred within 90 days after birth in 24 infants of women in the vaccine group and 56 infants of women in the placebo group (vaccine efficacy, 57.1%; 99.5% CI, 14.7 to 79.8); these results did not meet the statistical success criterion. No safety signals were detected in maternal participants or in infants and toddlers up to 24 months of age. The incidences of adverse events reported within 1 month after injection or within 1 month after birth were similar in the vaccine group (13.8% of women and 37.1% of infants) and the placebo group (13.1% and 34.5%, respectively). CONCLUSIONS: RSVpreF vaccine administered during pregnancy was effective against medically attended severe RSV-associated lower respiratory tract illness in infants, and no safety concerns were identified. (Funded by Pfizer; MATISSE ClinicalTrials.gov number, NCT04424316.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory Tract InfectionsFemaleHumansInfantInfant, NewbornPregnancyAntibodies, ViralCommunicable DiseasesDouble-Blind MethodInjections, IntramuscularRespiratory Syncytial VirusesTreatment OutcomeVaccinationVaccine EfficacyVaccines, Combined

Substanzen

Antibodies, ViralRespiratory Syncytial Virus VaccinesVaccines, Combined

Autor:innen und Institutionen

  • From the Medical Research Council Unit the Gambia, London School of Hygiene and Tropical Medicine, Fajara, Gambia (B.K.); the Institute for International Health Charité, Universitätsmedizin, Berlin (B.K.); the South Afr…

ORCID-Profile: Shabir A Madhi, Julia Glanternik, Kena A Swanson

Förderung

  • Medical Research Council
  • Pfizer

Zitieren

APA

Kampmann, B., Madhi, S. A., Munjal, I., Simões, E. A. F., Pahud, B. A., Llapur, C., Baker, J., Pérez Marc, G., Radley, D., Shittu, E., Glanternik, J., Snaggs, H., Baber, J., Zachariah, P., Barnabas, S. L., Fausett, M., Adam, T., Perreras, N., Van Houten, M. A., …, & MATISSE Study Group (2023). Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. New England Journal of Medicine, 388(16), 1451-1464. https://doi.org/10.1056/nejmoa2216480

Vancouver

Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. New England Journal of Medicine. 2023;388(16):1451-1464. doi:10.1056/nejmoa2216480

BibTeX
@article{Kampmann2023,
  author = {Kampmann, Beate and Madhi, Shabir A and Munjal, Iona and Simões, Eric A F and Pahud, Barbara A and Llapur, Conrado and Baker, Jeffrey and Pérez Marc, Gonzalo and Radley, David and Shittu, Emma and Glanternik, Julia and Snaggs, Hasra and Baber, James and Zachariah, Philip and Barnabas, Shaun L and Fausett, Merlin and Adam, Tyler and Perreras, Nicole and Van Houten, Marlies A and Kantele, Anu and Huang, Li-Min and Bont, Louis J and Otsuki, Takeo and Vargas, Sergio L and Gullam, Joanna and Tapiero, Bruce and Stein, Renato T and Polack, Fernando P and Zar, Heather J and Staerke, Nina B and Duron Padilla, María and Richmond, Peter C and Koury, Kenneth and Schneider, Katherine and Kalinina, Elena V and Cooper, David and Jansen, Kathrin U and Anderson, Annaliesa S and Swanson, Kena A and Gruber, William C and Gurtman, Alejandra and MATISSE Study Group, MATISSE Study Group},
  title = {Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {16},
  pages = {1451--1464},
  doi = {10.1056/nejmoa2216480}
}
Kostenlos starten →